MYC and cancer: Pre-clinical work indicated more growth inhibitory activity of AurA inhibitors on cancer cells with MYC oncogene amplifications and/or mutations in the Wnt/β-catenin pathway with decreased MYC protein expression in the presence of AurA kinase inhibition,16,17 but this could not be confirmed clinically.23 In conclusion, these genetic aberrations do not seem to have potential as a predictive biomarker for TAS-119.